The FLORA two study's overall survival benefit was so compelling that clinicians should now default to osimertinib plus chemotherapy for most first-line EGFR-mutant NSCLC patients, only opting out for specific reasons like comorbidities or patient preference.

Even if randomized trials show zongertinib's efficacy is merely comparable to chemoimmunotherapy, its significantly milder safety profile—especially its lack of cardiac toxicity and manageable side effects—is expected to make it the preferred first-line choice. Patient quality of life and tolerability are becoming decisive factors in treatment selection.

Due to a 10-11 month overall survival benefit shown in the FLORA two regimen, leading oncologists now consider osimertinib plus chemotherapy the standard first-line treatment for metastatic EGFR-mutant NSCLC. Monotherapy is reserved only for patients who cannot tolerate or refuse chemotherapy.

For patients with actionable mutations like EGFR or ALK, targeted therapy is the priority, regardless of PD-L1 score. Starting immunotherapy first in these patients can significantly increase the risk of developing severe pneumonitis (ILD) when they later switch to targeted therapy like osimertinib.

In the LEAP-010 trial, the combination arm's higher efficacy was offset by significantly greater toxicity (67% vs 38% severe adverse events). This increased treatment burden likely limited sustained therapy and prevented patients from receiving subsequent treatments, ultimately nullifying any survival benefit from improved tumor response.

While pan-RAS inhibitors like daraxoracib show broad efficacy irrespective of mutation, allele-specific agents may have fewer side effects and more predictable resistance patterns. This creates a clinical trade-off between immediate applicability and a more tailored, potentially better-tolerated long-term strategy.

For N2+ EGFR-mutant NSCLC, clinicians now face a choice. Combining neoadjuvant osimertinib with chemotherapy is potent and gets treatment done upfront, but osimertinib monotherapy is better tolerated, reducing the risk of toxicity that could prevent a patient from reaching their planned surgery.

The era of sequential monotherapy is over. Trials like FLORA2 (Osimertinib + chemo) show significant progression-free and overall survival benefits, making intensified upfront treatment the new standard of care for most patients, marking a major paradigm shift in treatment.

The clinical mindset for first-line EGFR-mutated lung cancer has flipped. Instead of asking who to escalate to intensified therapy, the new paradigm starts with combination treatment as the default. The focus is now on identifying specific patients (e.g., older, frail) for whom de-escalation to monotherapy is appropriate.